Week March 26th, 2004 through April 1st, 2004 |
Capital Hunter has a new tool that provides non subscribers and subscribers the ability to identify active investors based on their specific criteria. Please visit www.capitalhunter.com |
|
|
|
Over $462 million of venture capital was invested in 31 U.S.-based companies during this reporting period. The average deal size was approximately $14.9 million. The amount of venture capital invested this period is down 7% from last week's $499 million.
|
|
|
|
|
|
Geographically, 16 California companies raised $188 million in venture financings. The largest venture financing in California this period was by Salmedix, Inc. for $45 million. Salmedix, Inc. is located in San Diego, CA and is dedicated to creating value for patients, oncologists, and investors by developing cancer drugs, with an initial commercial focus on hematologic cancers.
|
|
|
|
|
The Biotech sector raised 39% of the venture capital this period. Four Biotech companies raised $182.9 million in venture financings. The largest venture financing in the Biotech sector this period was by EXIMIAS Pharmaceutical Corporation for $63.5 million. EXIMIAS Pharmaceutical Corporation focuses on the acquisition, development and commercialization of unique oncology and infectious disease products.
|
|
|
|
|
Companies raising their later rounds of funding represented 33% of the total venture capital deployed this period. The largest later stage financing was by EXIMIAS Pharmaceutical Corporation. To learn more about this deal and many others please visit www.capitalhunter.com and obtain a free two week trial to our service.
|
|
|
|
|
|
The three largest venture deals this period are as follows:
|
|
|
Company |
Industry |
Investment |
|
1 |
EXIMIAS Pharmaceutical Corporation |
Biotechnology |
$63.5 million |
|
2 |
Fingerhut Direct Marketing, Inc. |
Online Retail |
$62.5 million |
|
3 |
Salmedix, Inc. |
Biotechnology |
$45 million |
|
|
|
|
The following sixteen investors funded the above mentioned top three venture capital investments in excess of $171 million:
|
|
1
|
Bain Capital Ventures |
|
2
|
Battery Ventures |
|
3
|
Birchmere Ventures |
|
4
|
Clariden Bank |
|
5
|
Cross Atlantic Partners |
|
6
|
Easton Hunt Capital Partners (2) |
|
7
|
Emerging Technology Partners |
|
8
|
H.I.G. Ventures |
|
9
|
Hunt Ventures |
|
10
|
New Enterprise Associates |
|
11
|
Novo A/S |
|
12
|
OrbiMed Advisors (2) |
|
13
|
Pacific Rim Ventures |
|
14
|
Quaker BioVentures |
|
15
|
Quilvest Group |
|
16
|
Tom Petters |
|
A total of 70 equity financings of private and public companies occurred during this reporting period. Each of the 70 equity financings are profiled in a weekly report as well as over 30,000 other historic equity financings that you can obtain as a subscriber. Our profiles are of angel financings, venture financings, PIPE, public secondary and initial public equity offerings. If you are interested in obtaining detailed information about any of these or of the over 30,000 historic financings in our database please go to www.capitalhunter.com and get immediate access for free for a two week trial period. A subscription is only $19.95 per month. |
|
|
|
©2003 Capital Hunter, Inc. all rights reserved
|
To be REMOVED from this free service, CLICK HERE |
